Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC) Meeting Abstract
| Authors: | Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; Nadal, E.; Offin, M. D.; Pulla, M. P.; Ramalingam, S. S.; Smit, E. F.; Tsao, A. S.; Alcasid, A.; Usari, T.; Wilner, K.; Johnson, B. |
| Abstract Title: | Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | 1246 |
| End Page: | 1247 |
| Language: | English |
| ACCESSION: | WOS:001326612903065 |
| DOI: | 10.1016/j.annonc.2024.08.2298 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA56 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work